EUTECNIQ Sciences

See every page on one mapArrow keys move through results · Enter opens · Esc closes

EUTECNIQ Sciences

Engineering Nature into the Next Generation of Science.

A company in formation, building one documented pathway for botanical ingredients: identity, extraction, delivery, safety, regulation, scale-up and commercialization, with every external fact cited.

Find what you need Explore the platform

Status. The laboratory, plant and team shown here are proposed; none operates yet. Simulations are labeled.

From plant to product in seven proposed steps; select a step to open the page that explains itSchematic, not to scale
Proposed plant-to-product train: raw botanical material is identified, milled, extracted, purified, concentrated and spray dried into a packed ingredient; samples from four points go to the quality-control laboratory, release issues the specification and certificate of analysis, and one digital record holds every result. Schematic, not to scale.1Raw materialidentity at receipt2Millingparticle size set3Extractionsolvent, time,temperature4Purificationsolids out, resin orcolumn5Concentrationsolvent recovered6Spray dryingpowder collected7Ingredienttested and releasedRaw material: open the pageMilling: open the pageExtraction: open the pageMPurification: open the pageConcentration: open the pageSpray drying: open the pageIngredient: open the pageAnalytical and quality-control laboratory: open the pageAnalytical and quality-control laboratoryidentity, assay, contaminants, stabilityRelease: open the pageReleasespecification and COADigital record: open the pageOne digital record of every sample, result and decision (proposed)plant solidssolvent and extract solutionproductspent solidssample or recordProposed plant-to-product train: raw botanical material is identified, milled, extracted, purified, concentrated and spray dried into a packed ingredient; samples from four points go to the quality-control laboratory, release issues the specification and certificate of analysis, and one digital record holds every result. Schematic, not to scale.Raw material: open the page1Raw materialidentity at receiptMilling: open the page2Millingparticle size setExtraction: open the page3Extractionsolvent, time, temperaturePurification: open the page4Purificationsolids out, resin or columnConcentration: open the page5Concentrationsolvent recoveredSpray drying: open the page6Spray dryingpowder collectedIngredient: open the page7Ingredienttested and releasedAnalytical and quality-control laboratory: open the pageAnalytical and quality-control laboratoryidentity, assay, contaminants, stabilityRelease: open the pageReleasespecification and COADigital record: open the pageOne digital record of every sample, result anddecision (proposed)
  1. 1 Raw material and identity
  2. 2 Milling and processability
  3. 3 Extraction
  4. 4 Purification
  5. 5 Concentration
  6. 6 Spray drying
  7. 7 Ingredient and documents
  8. Analytical laboratory
  9. Release and COA
  10. Digital record
A generic botanical-extract train for orientation; real trains differ by plant, solvent and product. No site, equipment or capacity has been selected.
Find what you need

Seven sections, every page one click from this map

Every page as a tile inside its section; select a tile to open the pageSite structure
Built from the site navigation at publication. Tooltips give each page's figure and tool counts; the site map lists every page.
The approach

One program with one record stops weak candidates while stopping is still cheap

Eight stages, one record, and a written gate after every stageProposed
Eight proposed stages run as one program: source, identity, characterization, safety and interactions, delivery engineering, process scale-up, regulatory strategy and commercial outcome; a written gate follows each stage and can stop a candidate, most often early when stopping is cheap; every stage writes to one structured data recordSourceIdentityCharacterizationSafety andinteractionsDeliveryengineeringProcessscale-upRegulatorystrategyCommercialoutcomeSupplier, originand plant partdocumentedOrthogonalmethods confirmwhat it isChemistry,variability andcontaminantsHazards,exposure andmarginsFormat, stabilityand dispersionReproducible atpilot and plantscalePathway matchedto claims andmarketsIngredient,technology orlicensable IPStop at a written gateCost of a stop rises from left to right (qualitative)Most candidates should stop early, when stopping is cheapOne structured data record, from source material to specificationBetter-characterized ingredientsIdentity, composition and variabilitymeasured, not assumedMore defensible safety evidenceStudies chosen for the ingredient'sactual hazards and exposureReproducible specificationsLimits set on real lot data andcontrolled through scale-upCleaner technology transferProcess knowledge documented soa manufacturer can repeat itEight proposed stages as one program, with a written gate after each, early stops and one data recordSourceSupplier, origin and plant part documentedIdentityOrthogonal methods confirm what it isCharacterizationChemistry, variability and contaminantsSafety and interactionsHazards, exposure and marginsDelivery engineeringFormat, stability and dispersionProcess scale-upReproducible at pilot and plant scaleRegulatory strategyPathway matched to claims and marketsCommercial outcomeIngredient, technology or licensable IP◆Written gate after each stageStopRecorded at the gate; cheapest early, costlier later(qualitative)▮One structured data record, from source material tospecificationBetter-characterized ingredientsIdentity, composition and variability measured, notassumedMore defensible safety evidenceStudies chosen for the ingredient's actual hazards andexposureReproducible specificationsLimits set on real lot data and controlled through scale-upCleaner technology transferProcess knowledge documented so a manufacturer canrepeat it
Proposed EUTECNIQ pathway. The rising cost of a stop is qualitative; no figures are implied.
Separate vendors split the record and stop candidates late; one program keeps one record and stops them earlyProposed model
Two ways to organize the same work. Separate vendors split the data record, hand each other documents, stop candidates late and pass the manufacturer a formula and test methods. The proposed integrated program keeps one record, stops candidates at written gates as early as the evidence allows and passes a transfer packageSeparate vendors foreach stepLaboratoriespart of the data recordFormulatorspart of the data recordConsultantspart of the data recordManufacturerspart of the data recordstopped lateoften stopped after formulation or safety money is spentRecord split across labs, formulators, consultants and manufacturers; each hands the next a documentSpecifications from supplier certificates and literature ranges; regulatory pathway chosen after the product isdesignedManufacturergetsA formula and testmethodsProposed integratedprogramOne programone structured recordstopped earlystopped at written gates, as early as the evidence allowsOne structured record from source material to specificationSpecifications from measured variability and process capability; pathway chosen before the ingredient designis fixedManufacturergetsA transfer packagewith processknowledge andcontrol limitsSeparate vendors compared with the proposed integrated programSeparate vendors for each stepRecord split across labs, formulators, consultants andmanufacturersEach hands the next a documentCandidates often stopped after formulation or safetymoney is spentSpecifications from supplier certificates and literaturerangesRegulatory pathway chosen after the product isdesignedManufacturer gets a formula and test methodsProposed integrated programOne structured record from source material tospecificationCandidates stopped at written gates, as early as theevidence allowsSpecifications from measured variability and processcapabilityRegulatory pathway chosen before the ingredientdesign is fixedManufacturer gets a transfer package with processknowledge and control limits
Two ways to organize the same work, not a description of any company. Named operating models: how EUTECNIQ differs.

Questions that sink a botanical ingredient sit between disciplines: identity, variability, contaminants, safety, format, scale-up, pathway and evidence.

Explanation, details and sources

Sourcing, identity testing, extraction, formulation, safety science, regulatory work and manufacturing are usually bought from different organizations. Each hands the next a document, and the questions that sink a botanical ingredient sit in the gaps. EUTECNIQ proposes to run the scientific stages as one program with one data record; a candidate moves forward only when the evidence for that stage is in hand.

Where those questions usually surface, and what would catch each one earlier:

Where botanical ingredient programs commonly fail, and which discipline catches the problem early
Failure pointWhere it usually surfacesWhat catches it early
Uncertain identity or adulterationAfter purchase, in a customer's incoming test or a retailer auditOrthogonal identity methods and chemical fingerprints at receipt
Geographic and seasonal chemical variabilityLot-to-lot potency drift after launchChemotype mapping and specifications set on real variability
Contaminants (metals, pesticides, mycotoxins, microbes)Release testing, or a recallRisk-based testing tied to origin and processing
Intrinsic toxicity and drug interactionsSafety review late in developmentLiterature and exposure assessment before formulation spending
Poor solubility, stability or tastePrototype failure in the customer's formatPhysicochemical profiling that selects the delivery approach
Weak reproducibilityScale-up and the first commercial lotsProcess understanding: mass transfer, heat transfer, controls
Unclear regulatory pathwayWhen a claim, a format or a market changesPathway analysis before the ingredient design is fixed
Incomplete commercial evidenceCustomer due diligenceA planned evidence package matched to the intended claims

A qualitative map of failure modes discussed in the regulatory and scientific literature cited on the linked pages. It is not a statistic about any company or market.

Text version of the first figure, the eight proposed stages in order:

  1. SourceSupplier, origin and plant part documented
  2. IdentityOrthogonal methods confirm what it is
  3. CharacterizationChemistry, variability and contaminants
  4. Safety and interactionsHazards, exposure and margins
  5. Delivery engineeringFormat, stability and dispersion
  6. Process scale-upReproducible at pilot and plant scale
  7. Regulatory strategyPathway matched to claims and markets
  8. Commercial outcomeIngredient, technology or licensable IP

Text version of the second figure, the same work organized two ways:

A fragmented service model compared with the proposed integrated model
QuestionSeparate vendors for each stepProposed integrated program
Who holds the full data record?Split across labs, formulators, consultants and manufacturersOne structured record from source material to specification
When is a candidate stopped?Often after formulation or safety money is spentAt written gates, as early as the evidence allows
How are specifications set?From supplier certificates and literature rangesFrom measured variability and process capability
How is the regulatory pathway chosen?After the product is designedBefore the ingredient design is fixed
What reaches the manufacturer?A formula and test methodsA transfer package with process knowledge and control limits

See how the platform would work, stage by stage →

Market context

U.S. herbal supplement sales nearly doubled between 2015 and 2024

U.S. retail sales of herbal supplements by channel, 2015–2024, with compound annual growthThird-party estimate
U.S. retail sales of herbal supplements, 2015 to 2024, stacked by channel: from 6.92 to 13.23 billion dollars, a compound annual growth of 7.5% in nominal dollars and 4.2% after inflation. Third-party estimates (Nutrition Business Journal).02468101214US$ billion2015, Mass market: US$1.204 billion2015, Natural and health food: US$2.356 billion2015, Direct sales: US$3.363 billion6.920152016, Mass market: US$1.336 billion2016, Natural and health food: US$2.506 billion2016, Direct sales: US$3.609 billion7.520162017, Mass market: US$1.449 billion2017, Natural and health food: US$2.624 billion2017, Direct sales: US$3.984 billion8.120172018, Mass market: US$1.558 billion2018, Natural and health food: US$2.804 billion2018, Direct sales: US$4.408 billion8.820182019, Mass market: US$1.704 billion2019, Natural and health food: US$2.904 billion2019, Direct sales: US$4.913 billion9.520192020, Mass market: US$2.131 billion2020, Natural and health food: US$2.950 billion2020, Direct sales: US$6.076 billion11.220202021, Mass market: US$2.205 billion2021, Natural and health food: US$2.992 billion2021, Direct sales: US$7.033 billion12.220212022, Mass market: US$2.350 billion2022, Natural and health food: US$2.984 billion2022, Direct sales: US$6.674 billion12.020222023, Mass market: US$2.484 billion2023, Natural and health food: US$3.040 billion2023, Direct sales: US$7.027 billion12.620232024, Mass market: US$2.607 billion2024, Natural and health food: US$3.121 billion2024, Direct sales: US$7.503 billion13.22024Direct salesNatural and health foodMass marketGrowth, 2015–20247.5%a year, nominal dollars4.2%a year in 2024 dollars (CPI-U)Compound annual growth rate= (end / start)1/9​ − 1
Source: Nutrition Business Journal estimates published in Smith T, Lang C, Craft E, HerbalGram 144 (2025), Tables 1 (totals) and 3 (channels); inflation adjustment with BLS CPI-U annual averages. Retrieved October 2026.
Data table
U.S. herbal supplement retail sales by channel, US$ billion (NBJ estimates in HerbalGram 144, Tables 1 and 3)
YearMass marketNatural and health foodDirect salesTotalTotal in 2024 dollars
20151.2042.3563.3636.9229.161
20161.3362.5063.6097.4529.740
20171.4492.6243.9848.05710.311
20181.5582.8044.4088.77810.966
20191.7042.9044.9139.53011.693
20202.1312.9506.07611.16813.536
20212.2052.9927.03312.24114.171
20222.3502.9846.67412.01812.882
20232.4843.0407.02712.55112.921
20242.6073.1217.50313.23113.231

These are industry sales estimates, not EUTECNIQ revenue or a market EUTECNIQ would capture. Market dashboard →

Evidence

Every figure and claim carries a label saying what kind of evidence it is

Vanillin, computed surface charge: where the molecule can donate or accept hydrogen bondsComputed, not measured
Our own density-functional calculation (BP86/def2-SVP in a perfect-conductor continuum); COSMO-type models use this surface to estimate solvent interactions. Drag or use the arrow keys to rotate. Method and data
What each section rests on: share of its evidence labels by kindCounted at build time
SectionShare of the section’s evidence labelsLabels
Platform138
Technologies365
Applications237
Regulatory & Safety267
Scientific Insights362
Academy256
Company95
Verified dataPeer-reviewedRegulation or guidanceThird-party estimateProposal, partner or riskSimulation or schematic
Every evidence label on every page of each section, counted when the site is built. The label key is on the insights library.
Data table
Evidence labels by section, counted at build time
SectionLabelsVerified dataPeer-reviewedRegulation or guidanceThird-party estimateProposal, partner or riskSimulation or schematic
Platform13822 (16%)0 (0%)32 (23%)1 (1%)58 (42%)25 (18%)
Technologies36552 (14%)56 (15%)28 (8%)0 (0%)80 (22%)149 (41%)
Applications23729 (12%)12 (5%)71 (30%)0 (0%)111 (47%)14 (6%)
Regulatory & Safety26731 (12%)6 (2%)159 (60%)0 (0%)47 (18%)24 (9%)
Scientific Insights362100 (28%)69 (19%)15 (4%)20 (6%)60 (17%)98 (27%)
Academy25661 (24%)56 (22%)48 (19%)0 (0%)16 (6%)75 (29%)
Company9521 (22%)11 (12%)6 (6%)2 (2%)52 (55%)3 (3%)

No label exists for EUTECNIQ experimental results, because none exist yet.

Global ingredients

A foreign certificate is not U.S. market access; six proposed steps would build what is missing

Six proposed steps from an international supplier to a qualified U.S. ingredientProposed
A foreign certificate of analysis or GMP certificate does not by itself establish that an ingredient may be marketed in the United States; six proposed steps from supplier qualification to a supply agreement would build the evidence and documents a U.S. buyer needsForeign certificateCertificate of analysis orGMP certificateQualifiedsupplierAnalytical andsafetydevelopmentRegulatorystrategyFormulationimprovementU.S.distributionSupplyagreementAudit, qualityagreement,traceabilityIdentity,contaminants,safety dossierStatusanalysis foreachintended useStability,dispersion,deliveryformatImportcomplianceand technicalsupportSpecificationsand changecontrolU.S.manufacturersand brands≠Evidence and documents that would close the gap · proposed business models; no agreement signedA certificate alone does not establish that an ingredient may be marketed in the U.S.Six proposed steps from a foreign certificate to a U.S. supply agreementForeign certificate of analysis or GMP certificateDoes not by itself establish that the ingredient may bemarketed in the U.S.1 · Qualified supplierAudit, quality agreement, traceability2 · Analytical and safety developmentIdentity, contaminants, safety dossier3 · Regulatory strategyStatus analysis for each intended use4 · Formulation improvementStability, dispersion, delivery format5 · U.S. distributionImport compliance and technical support6 · Supply agreementSpecifications and change controlU.S. manufacturers and brandsProposed business models; no supply, distribution orexclusivity agreement signed
Proposed business models only. No supply, distribution or exclusivity agreement has been signed.
Text version of the six steps
  1. Qualified supplierAudit, quality agreement, traceability
  2. Analytical and safety developmentIdentity, contaminants, safety dossier
  3. Regulatory strategyStatus analysis for each intended use
  4. Formulation improvementStability, dispersion, delivery format
  5. U.S. distributionImport compliance and technical support
  6. Supply agreementSpecifications and change control
For international manufacturers For U.S. manufacturers and brands
Explanation, details and sources

A foreign certificate of analysis or GMP certificate does not by itself establish that an ingredient may be marketed in the United States. EUTECNIQ proposes to build the evidence and documentation that close that gap.

Founder

The founder's reported roles span molecular design, laboratories and cGMP production

Five roles since 2007, each adding a capability the platform would combineFounder-reported
Founder career 2007 to 2026 in five roles, with the capability layer each role addedPaad Energy Consulting, 2007–2011: Senior process engineer, industrial extraction and separationPaad Energy Consulting2007–2011University of Colorado Denver, 2011–2015: Doctoral research, Civil Engineering programPh.D., CU Denver2011–2015Yazaki Technology Center of America, 2015–2021: Senior R&D staff and program lead, advanced materialsYazaki2015–2021MilliporeSigma, 2021–2023: Head of plant process engineering and MSATMilliporeSigma2021–2023Botanic Tonics, 2023–present: Director of R&D and quality control, then senior director of product developmentBotanic Tonics2023–presentSeparation processes: from 2007Separation processesMolecular design: from 2011Molecular designRegulated (cGMP) production: from 2021Regulated (cGMP) productionBotanical products: from 2023Botanical products2007200920112013201520172019202120232025Each role added a layerLayers start with the role that added themFounder career from 2007 to 2026: five roles in order, the capability layer each added, and the public recordCapability layer each role addedSeparation processes · from 2007Molecular design · from 2011Regulated (cGMP) production · from 2021Botanical products · from 2023Paad Energy Consulting2007–2011Paad Energy ConsultingSenior process engineer, industrial extractionand separationDesign, debottlenecking and energyoptimization of solvent extraction unitsUniversity of Colorado Denver2011–2015University of Colorado DenverDoctoral research, Civil Engineering programOptimization-based design of ionic liquids, withlife-cycle and ecotoxicity assessmentYazaki Technology Center of America2015–2021Yazaki Technology Center of AmericaSenior R&D staff and program lead, advancedmaterialsIonic-liquid working fluids taken from molecularmodeling to 10 kg pilot scaleMilliporeSigma2021–2023MilliporeSigmaHead of plant process engineering and MSATSix-site cGMP network for APIs andoligonucleotides, kilo laboratory to2,000-gallon scaleBotanic Tonics2023–presentBotanic TonicsDirector of R&D and quality control, then seniordirector of product developmentBotanical products under 21 CFR Part 111 andan in-house analytical laboratorySeparation processes: from 2007Molecular design: from 2011Regulated (cGMP) production: from 2021Botanical products: from 2023Public record, checked Oct 22, 2026Ph.D., University of Colorado Denver, 201513 publications, 2010–20166 patents granted 2019–2023, Yazaki-assigned: 3 active, 3lapsed403 citations (Semantic Scholar)
Roles and dates as the founder reports them; the Ph.D. (University of Colorado Denver, 2015) is public record. Details and sources on the founder page.

Dr. Amir H. Mehrkesh is a process engineer and formulation scientist with about 15 years in botanical products, pharmaceutical manufacturing, specialty chemicals and advanced materials. Full record →

Explanation, details and sources

His public record includes a Ph.D. from the University of Colorado Denver (2015) on the optimization-based design of ionic liquids, peer-reviewed publications, and granted patents in the United States, Japan and Europe that are assigned to Yazaki Corporation, his former employer. They are not EUTECNIQ assets.

He is of Persian heritage, and the company cites that medical tradition only through published scholarship. Persian medical heritage →

  • Founder-reportedLed a 37-person process engineering and operations organization across a six-site cGMP network producing APIs and oligonucleotides (MilliporeSigma).
  • Founder-reportedBuilt an R&D and quality-control team and an in-house laboratory supporting 21 CFR Part 111 quality workflows at a U.S. botanical beverage company.
  • Founder-reportedUsed COSMO-RS molecular modeling, design of experiments and machine learning to focus experimental work in advanced-materials R&D (Yazaki).

Start a conversation

Every inquiry reaches the founder. Please send no confidential formulas in a first message.

Brands and ingredient makers International suppliers Research collaborators Strategic investors